Markus Knuf

6.4k total citations · 1 hit paper
139 papers, 3.9k citations indexed

About

Markus Knuf is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Markus Knuf has authored 139 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Epidemiology, 50 papers in Microbiology and 28 papers in Infectious Diseases. Recurrent topics in Markus Knuf's work include Pneumonia and Respiratory Infections (56 papers), Bacterial Infections and Vaccines (50 papers) and Influenza Virus Research Studies (38 papers). Markus Knuf is often cited by papers focused on Pneumonia and Respiratory Infections (56 papers), Bacterial Infections and Vaccines (50 papers) and Influenza Virus Research Studies (38 papers). Markus Knuf collaborates with scholars based in Germany, Belgium and United States. Markus Knuf's co-authors include Fred Zepp, Ralf Clemens, B. Ruf, Peter Wutzler, Heinz‐Josef Schmitt, Pirmin Habermehl, Theodore F. Tsai, Timo Vesikari, Lode Schuerman and Dorothee Kieninger‐Baum and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Markus Knuf

133 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

2023 175 citations Simon B. Drysdale, Katrina Cathie et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Markus Knuf

Since Specialization

Citations

This map shows the geographic impact of Markus Knuf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Knuf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Knuf more than expected).

Fields of papers citing papers by Markus Knuf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Knuf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Knuf. The network helps show where Markus Knuf may publish in the future.

Co-authorship network of co-authors of Markus Knuf

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Knuf. A scholar is included among the top collaborators of Markus Knuf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Knuf. Markus Knuf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P-631. RSV Prophylaxis with Nirsevimab in Infants: Systematic Review of Early Real-World Evidence on Effectiveness and Impact 2025 ·Open Forum Infectious Diseases ·(unknown), Anna C. Meyer, Oliver Damm, (unknown), (unknown), Rolf Kramer, Markus Knuf	1
2	Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination 2024 ·Expert Review of Vaccines ·(unknown), Markus Knuf, Marco Aurélio Palazzi Sáfadi, Jamie Findlow	2
3	Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants breakdown → 2023 ·New England Journal of Medicine ·Simon B. Drysdale, Katrina Cathie, Florence Flamein, Markus Knuf, Andrea M. Collins, Helen Hill, Friedrich W. Kaiser, Jonathan Cohen, Didier Pinquier, (unknown), (unknown), Jing Jin, Mathieu Bangert, Karine Mari, (unknown), (unknown), Michelle Roberts, Pierre Tissières, Simon Royal, Saul N. Faust	175
4	Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review 2023 ·Human Vaccines & Immunotherapeutics ·Markus Knuf, Marie‐Laure Charkaluk, (unknown), Ignacio Salamanca de la Cueva, (unknown), Lauren Mason, (unknown), (unknown)	2
5	Epidemiology and economic burden of meningococcal disease in Germany: A systematic review 2022 ·Vaccine ·(unknown), Julian Witte, Wolfgang Greiner, Oliver Damm, (unknown), Rolf Kramer, Markus Knuf	11
6	Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations 2021 ·Pathogens and Global Health ·Federico Martinón‐Torres, Muhamed‐Kheir Taha, Markus Knuf, Victoria Abbing‐Karahagopian, Michele Pellegrini, Rafik Bekkat-Berkani, Véronique Abitbol	29
7	Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines 2021 ·Expert Review of Vaccines ·Piyali Mukherjee, (unknown), (unknown), Markus Knuf, Sven‐Arne Silfverdal, Pope Kosalaraksa, Attila Mihalyi	6
8	Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines 2021 ·Human Vaccines & Immunotherapeutics ·Lidia Serra, Markus Knuf, Federico Martinón‐Torres, (unknown), Jamie Findlow	10
9	Hexavalent vaccines: What can we learn from head-to-head studies? 2021 ·Vaccine ·Markus Knuf, H. Haas, Pilar Garcı́a-Corbeira, (unknown), Piyali Mukherjee, (unknown), (unknown)	9
10	Functional analysis and associated factors of the peripapillary retinal nerve fibre layer in former preterm and full-term infants 2017 ·British Journal of Ophthalmology ·Achim Fieß, (unknown), (unknown), (unknown), Markus Knuf, Bernd Kirchhof, Philipp S. Muether, Jacqueline Bauer, (unknown)	30
11	Prevalence and associated factors of strabismus in former preterm and full-term infants between 4 and 10 Years of age 2017 ·BMC Ophthalmology ·Achim Fieß, (unknown), Alexander K. Schuster, Markus Knuf, Bernd Kirchhof, Philipp S. Muether, Jacqueline Bauer	40
12	Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children 2015 ·Human Vaccines & Immunotherapeutics ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Luis Rivera, Paola Pedotti, Ashwani Kumar Arora, Maria Lattanzi, Dorothee Kieninger, Giovanni Della Cioppa	11
13	Disease Burden of Rotavirus Gastroenteritis in Children Residing in Germany 2015 ·The Pediatric Infectious Disease Journal ·Frank Kowalzik, Fred Zepp, Isabell Hoffmann, Harald Binder, (unknown), Reyn van Ewijk, Markus Knuf, Tobias Tenenbaum, Martin W. Laaß, (unknown), Renate Schulze‐Rath, Manuela Marron	8
14	Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age 2014 ·The Pediatric Infectious Disease Journal ·Markus Knuf, Geert Leroux‐Roels, H. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Kumar Arora, Dorothee Kieninger‐Baum, Giovanni Della Cioppa	10
15	Detection of Respiratory Viral Infections in Neonates Treated for Suspicion of Nosocomial Bacterial Sepsis 2013 ·The Pediatric Infectious Disease Journal ·André Kidszun, (unknown), (unknown), Britta Gröndahl, Markus Knuf, (unknown), Eva Mildenberger	19
16	Do We Know When, What and For How Long to Treat? 2012 ·The Pediatric Infectious Disease Journal ·Susanna Esposito, Robert Cohen, Javier Díez‐Domingo, (unknown), David Greenberg, Ulrich Heininger, Markus Knuf, Irja Lutsar, Nicola Principi, Fernanda Rodrigues, Mike Sharland, Vana Spoulou, George A. Syrogiannopoulos, Vytautas Usonis, Anne Vergison, Urs B. Schaad	87
17	An assessment of prime‐boost vaccination schedules with AS03_A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults 2012 ·Influenza and Other Respiratory Viruses ·Paul Gillard, Adrian Caplanusi, Markus Knuf, François Roman, Karl Walravens, Philippe Moris, Mamadou Dramé, Tino F. Schwarz	28
18	Mid-term results of a modified arterial switch operation using the direct reconstruction technique of the pulmonary artery. 2010 ·PubMed ·(unknown), Christoph Kampmann, (unknown), Marc Hartert, Markus Knuf, Markus Heinemann, Christian‐Friedrich Vahl	2
19	Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children 2006 ·The Pediatric Infectious Disease Journal ·Markus Knuf, Pirmin Habermehl, Fred Zepp, W. Mannhardt, (unknown), (unknown), (unknown), (unknown), (unknown), Nadia Tornieporth, Dominique Descamps, Paul Willems	82
20	Lymphadenitis colli durch nichttuberkulöse Mykobakterien (NTM) im Kindesalter - Eine Fallserie und Literaturübersicht 2003 ·Klinische Pädiatrie ·Markus Knuf, Pirmin Habermehl, Fred Zepp, Peter Schmidtke, (unknown), Hans‐Iko Huppertz, Sabine Rüsch–Gerdes, (unknown), Frank Kowalzik, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact